Clinical complementary medicine and pharmacology最新文献

{"title":"The Antidiabetic Effect and Mechanism of JinXiaoXiaoKe Decoction in Type 2 Diabetic Goto–Kakizaki Rats","authors":"Miao Lin ,&nbsp;Lei Wang ,&nbsp;Lihua Wan ,&nbsp;Jiadong Xu ,&nbsp;Yu Li ,&nbsp;Lingyong Cao ,&nbsp;Shuyuan Lin","doi":"10.1016/j.ccmp.2022.100049","DOIUrl":"10.1016/j.ccmp.2022.100049","url":null,"abstract":"<div><h3>Background</h3><p>Modern research and clinical practice have proved that Traditional Chinese Medicine (TCM) has unique advantages in the treatment of diabetes. JinXiaoXiaoKe decoction (JXXKD) is a prescription for treating diabetes used in ancient China and still has a good clinical effect today. However, the mechanism of JXXKD against T2DM is unclear.</p></div><div><h3>Objective</h3><p>The purpose of this study is to screen the targets through network pharmacology, and to explore the therapeutic effect and mechanism of JXXKD on diabetic rats.</p></div><div><h3>Methods</h3><p>The JXXKD's active components, related targets and T2DM targets were obtained from the public database, and Venny 2.1 was used to determine the common targets of JXXKD in the treatment of T2DM, and PPI, GO and KEGG analysis were performed. The core components and targets are verified by molecular docking. The diabetic Goto–Kakizaki rat model was established by high-sugar and high-fat diet, Wistar rats were used as a blank control group. The diabetic rats were randomized into three groups and administered saline (MO), metformin (MET), or JXXKD once a day for 4 weeks. Fasting blood glucose (FBG), Fasting serum insulin (FINS), and HOMA-IR were detected, hematoxylin-eosin (HE) staining was used to observe the pathological changes of liver tissue; and qPCR was used to detect the expression of relevant genes screened by network pharmacology.</p></div><div><h3>Results</h3><p>93 active components and 296 targets of JXXKD were identified, of which 156 overlapped with T2DM-related targets. PPI network showed that <em>APP, AKT1, ANXA1, RXRA, C3, EGFR, ESR1, RELA, IL6</em>, and <em>MAPK8</em> were the top 10 relevant targets. GO analysis showed the common targets are mainly involved in oxidative stress, lipid metabolism, and nutrient levels, while KEGG analysis showed these targets may regulate lipids and atherosclerosis, AGE-RAGE signaling pathway, and TNF signaling pathway. Molecular docking suggested a satisfactory potential for key components to bind to these significant targets. The animal experiments showed that JXXKD significantly improved the symptoms of polyuria, decreased the protein levels of FBG and HOMA-IR, improved liver fat deposition, and decreased the gene expressions of <em>Foxo</em>1, <em>Pparg</em> and <em>Akt</em> in diabetic rats.</p></div><div><h3>Conclusion</h3><p>The mechanism of JXXKD treat T2DM may be achieved by modulating the expression of FOXO1, PPARG, and AKT, regulating the glucose and lipids metabolism.</p></div>","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"3 1","pages":"Article 100049"},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43122397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HEMATOLOGY: general questions","authors":"E. Belyaeva","doi":"10.12737/2409-3750-2023-8-4-2-13","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-2-13","url":null,"abstract":"General issues of hematology, hematological syndromes, functions of blood cells, changes in general clinical blood analysis are considered.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"92 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80927860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RED FLY AGARIC IN MODERN MEDICINE (short message)","authors":"M. Gorelikov","doi":"10.12737/2409-3750-2023-8-4-41-44","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-41-44","url":null,"abstract":"Preparations of red fly agaric have anti-anxiety, antidepressant, psychostimulating, analgesic effect. The aim of the study is to identify the antidepressant, psychostimulating activity of the red fly agaric in order to select a priority direction for further in–depth research. Material and method of research. A preclinical preliminary study of the results of taking powder from the caps of the mushroom fly agaric red by volunteers – subscribers of the telegram channel t.me/zhaxar555 , with subsequent statistical processing of the feedback result. The research method was a questionnaire, the questionnaire consisted of a Beck depression scale, a sleep disturbance scale, and an emotional state questionnaire. Results and their discussion. The drug of mushroom origin significantly increased the level of the emotional and personal sphere, improved sleep, increased physical activity, the level of the motivational sphere, reduced the level of depressed and anxious mood. Conclusion. The questionnaire revealed a good efficacy of taking the body of the mushroom mu-homor red in monotherapy of mild subdepressive disorder, which determines the prospect of studying the drug in a further clinical study.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"129 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82857519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of mycophenolate mofetil in interstitial lung diseases associated with rheumatic diseases","authors":"E. Ionova","doi":"10.12737/2409-3750-2023-8-4-13-19","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-13-19","url":null,"abstract":"Mycophenolate mofetil is an antimetabolite with a powerful inhibitory effect on the proliferation of T and B lymphocytes, the drug has been used since the early 1990s to prevent acute graft rejection after organ transplantation. It is also widely used for the treatment of various rheumatic diseases with lung damage. Interstitial lung disease is a heterogeneous group of progressive fibrotic lung diseases, which is often secondary to rheumatic disease and is a common cause of death. Mycophenolate mofetil is the main alternative to cyclophosphamide as a first-line drug for the treatment of interstitial lung diseases associated with rheumatic diseases, or as a possible maintenance therapy after treatment with cyclophosphamide with a lower frequency of side effects. However, the use of mycophenolate mofetil in interstitial lung diseases associated with rheumatic diseases has insufficient scientific data. The review describes current information and achievements in the field of application, efficacy and safety of mycophenolate mofetil.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"20 5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82905768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Secondary amyloidosis as a complication of rheumatoid arthritis in a patient with low adherence to treatment","authors":"D. Nikulina","doi":"10.12737/2409-3750-2023-8-4-35-40","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-35-40","url":null,"abstract":"A case of secondary amyloidosis in rheumatoid arthritis in a 28-year-old girl who did not receive sufficient basic therapy due to low adherence to treatment is presented. During the course of the disease, proteinuria developed, widespread edema, digestive disorders. The development of symptoms over time, the process of diagnosis, the selection of therapy, rehabilitation are demonstrated.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73415797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Problems of diagnosis and treatment of systemic lupus erythematosus in a young girl","authors":"L. Zhuravleva","doi":"10.12737/2409-3750-2023-8-4-30-32","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-30-32","url":null,"abstract":"The article describes a clinical case of acute systemic lupus erythematosus in a girl of reproductive age with secondary antiphospholipid syndrome. The diagnosis was made 1 year after the first clinical symptoms. The treatment was carried out with hormonal drugs, immunosuppressants and genetically engineered biological drugs.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"130 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79606119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Variants of the course of ankylosing spondylitis on the example of a clinical case of twin brothers","authors":"O. Dvornikova","doi":"10.12737/2409-3750-2023-8-4-25-29","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-25-29","url":null,"abstract":"The case of ankylosing spondylitis in twin brothers is considered. The influence of various factors on the trigger mechanism of the disease is analyzed. Both twin brothers have a genetic predisposition to the disease, but only one of them has provoking agents, in the form of injury and inflammation.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76074930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metastatic bone damage in prostate cancer as a cause of chronic musculoskeletal pain","authors":"O. Blashkevich","doi":"10.12737/2409-3750-2023-8-4-20-24","DOIUrl":"https://doi.org/10.12737/2409-3750-2023-8-4-20-24","url":null,"abstract":"A clinical case of detection of prostate cancer with multiple bone metastases is presented. It has been clearly demonstrated that oncopathology in the early stages may go unnoticed due to the absence of specific symptoms, as well as the ability to mimic other nosologies in clinical manifestations during its progression. The importance of oncological alertness on the part of the doctor is shown, the need for medical examination is once again emphasized.","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79876008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification and Functional Analysis of Serum Specific miRNAs in Recurrent Aphthous Stomatitis Patients with Excess-heat or Yin-deficiency","authors":"Jie Bao ,&nbsp;Zhengyang Zhu ,&nbsp;Xizhao Zhang ,&nbsp;Lin Huang ,&nbsp;Li Xu ,&nbsp;Xiaobing Dou ,&nbsp;Yongsheng Fan","doi":"10.1016/j.ccmp.2023.100079","DOIUrl":"https://doi.org/10.1016/j.ccmp.2023.100079","url":null,"abstract":"<div><h3>Background</h3><p>The treatment of Traditional Chinese Medicine (TCM) in recurrent aphthous stomatitis (RAS) based on syndrome differentiation has won the international acceptance, but the molecular mechanism of excess-heat syndrome and yin-deficiency syndrome of RAS remains unclear.</p></div><div><h3>Objective</h3><p>To clarify specific microRNAs (miRNAs) and their functions in RAS patients with excess-heat or yin-deficiency<strong>.</strong></p></div><div><h3>Methods</h3><p>Serum samples were collected from patients meeting the RAS diagnostic criteria of excess-heat or yin-deficiency syndrome and healthy individuals. Core miRNAs were then identified under miRNA microarray analyses. Target prediction and bioinformatic analyses were carried out and gene-pathway-networks were visualized to better understand the relationship between different genes and pathways.</p></div><div><h3>Results</h3><p>(1) 90 individuals meeting the inclusion criteria were collected in this study. Among them, 9 miRNAs were screened out in excess-heat syndrome group (EH group), with 1 upregulated and 8 downregulated. And four miRNAs (hsa-miR-20b-5p, hsa-miR-122–5p, hsa-miR-483–5p and hsa-miR-3197) were validated by real-time PCR method. 14 miRNAs were screened out in yin-deficiency syndrome group (YD group) (7 upregulated and 7 downregulated). And hsa-miR-17–5p, hsa-miR-106–5p and hsa-miR-20b-5p were validated. (2) A total of 4,776 target genes were identified in EH group which enriched in GO categories including nervous system development and calcium ion binding and pathway such as PI3K-Akt signaling pathway and Calcium signaling pathway. 10,172 target genes were identified in YD group which enriched GO categories included protein binding and positive regulation of transcription from RNA polymerase II promoter and pathway included MAPK signaling pathway and Ras signaling pathway.</p></div><div><h3>Conclusion</h3><p>Hsa-miR-20b-5p in patients with RAS could act as the novel target for the classification of the syndrome. It is upregulated in RAS patients with excess-heat syndrome while downregulated in patients with yin-deficiency syndrome. The PI3K-Akt and MAPK signaling pathways and their related target genes may provide new insights into the molecular mechanisms of RAS with excess-heat syndrome or yin-deficiency syndrome, respectively.</p></div>","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"3 4","pages":"Article 100079"},"PeriodicalIF":0.0,"publicationDate":"2023-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49724796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modulatory Effects of Mushrooms on the Inflammatory Signaling Pathways and Pro-inflammatory Mediators","authors":"Adekunle Rowaiye ,&nbsp;Olobayotan Ifeyomi Wilfred ,&nbsp;Olukemi Adejoke Onuh ,&nbsp;Doofan Bur ,&nbsp;Solomon Oni ,&nbsp;Ezinne Janefrances Nwonu ,&nbsp;Gordon Ibeanu ,&nbsp;Angus Nnamdi Oli ,&nbsp;Timipanipiri ThankGod Wood","doi":"10.1016/j.ccmp.2022.100037","DOIUrl":"10.1016/j.ccmp.2022.100037","url":null,"abstract":"<div><h3>Background</h3><p>Mushrooms include a wide variety of bioactive compounds that have been linked to therapeutic and nutritional benefits, making them a potential source of new medications and functional foods.</p></div><div><h3>Objective</h3><p>The goal of this study is to offer a complete overview of the mushroom's modulatory effects on inflammatory signaling pathways, which leads to the inhibition of inflammation in various types of immune cells and animal models.</p></div><div><h3>Methods</h3><p>This study reviewed the inhibitory effects of mushrooms on the inflammation process through the modulation of the pro-inflammatory mediators and associated signaling pathways. A literature search in PubMed and Google Scholar was conducted for the relevant original research and review articles on the anti-inflammatory effects of mushrooms. Related articles published in English were selected, studied and discussed.</p></div><div><h3>Results</h3><p>As revealed by the selected articles, bioactive molecules which include peptides, polysaccharides, terpenes, sterols, fatty acids, and phenols have been extracted from the powder, concentrate, and different solvent extracts of edible mushrooms. These bioactive molecules have shown significant efficacy in inhibiting the major pro-inflammatory biomarkers and associated pathways in <em>in vivo</em> and <em>in vitro</em> settings.</p></div><div><h3>Conclusion</h3><p>This review demonstrated that mushrooms significantly inhibit the production of pro-inflammatory mediators and can be developed for clinical use as anti-inflammatory agents. Further research is required to establish the comparative efficacy between mushrooms and NSAID especially in the <em>in vivo</em> inhibitory activity against the production of cyclooxygenase and pro-inflammatory cytokines.</p></div>","PeriodicalId":72608,"journal":{"name":"Clinical complementary medicine and pharmacology","volume":"2 4","pages":"Article 100037"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772371222000183/pdfft?md5=af04ebddc868ba88db7b910a10de37f3&pid=1-s2.0-S2772371222000183-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43890939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}